Dynamin-1 is a potential mediator in Cancer-Related Cognitive Impairment

Ding Quan Ng,Casey Hudson,Tracy Nguyen,Sukesh Kumar Gupta,Yong Qin Koh,Munjal M Acharya,Alexandre Chan
DOI: https://doi.org/10.1101/2024.06.04.597349
2024-06-06
Abstract:Dynamin-1 (DNM1) consolidates memory through synaptic transmission and modulation and has been explored as a therapeutic target in Alzheimer's disease. Through a two-prong approach, this study examined its role in cancer-related cognitive impairment (CRCI) pathogenesis using human and animal models. The human study recruited newly diagnosed, chemotherapy-naïve adolescent and young adult cancer and non-cancer controls to complete a cognitive instrument (FACT-Cog) and blood draws for up to three time points. Concurrently, a syngeneic young-adult WT (C57BL/6 female) mouse model of breast cancer was developed to study DNM1 expression in the brain. Samples from eighty-six participants with 30 adolescent and young adult (AYA) cancer and 56 non-cancer participants were analyzed. DNM1 levels were significantly lower among cancer participants compared to non-cancer prior to treatment. While receiving cancer treatment, cognitively impaired patients were found with a significant downregulation of DNM1, but not among those without impairment. In murine breast cancer-bearing mice receiving chemotherapy, we consistently found a significant decline in DNM1 immunoreactivity in the hippocampal CA1 and CA3 subregions. Observed in both human and animal studies, the downregulation of DNM1 is linked with the onset of CRCI. Future research should explore the potential of DNM1 in CRCI pathogenesis and therapeutics development.
Pathology
What problem does this paper attempt to address?
This paper investigates the role of Dynamin-1 in cancer-related cognitive impairment (CRCI). CRCI, also known as "chemo brain," refers to the decline in cognitive function that cancer patients experience after treatment. The study used a two-step approach. Firstly, in a human study, the differences in cognitive tests and blood samples were analyzed between adolescent and young adult cancer patients and a non-cancer control group. It was found that cancer patients had lower levels of Dynamin-1 even before treatment. Secondly, in a mouse model of breast cancer, the impact of chemotherapy on Dynamin-1 expression was examined, and it was found that Dynamin-1 expression in the hippocampus of chemotherapy-treated mice significantly decreased. The keywords of the paper include cancer-related cognitive impairment, chemo brain, Dynamin-1, exosomes, and exosome. The research findings suggest that the downregulation of Dynamin-1 may be related to the occurrence of CRCI, and future research should further explore the potential role of Dynamin-1 in the pathogenesis and treatment of CRCI.